LRMR
Larimar Therapeutics, Inc.
$3.61
+0.20 (+5.87%)
At close · Jul 8
Market Cap
$375.02M
Shares
103,882,937
Price & Indicators
Indicators
Price
Panels
Event markers
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$3.61
Open$3.42
Day$3.41–3.64
52W$2.72–6.42
Avg vol 30d2.4M
Short int10.5M · 10.1% float · 5.1d
Short vol38%
Last earningsMay 14, 2026
DataJan 2020–Jul 2026
Filing10-Q · May 14
Equibles Rating
blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 16.9 · calm
Equity put/call 0.86
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−9%
below
Price vs 50-day avg
−0%
below
RSI (14)
54
neutral
MACD trend
Positive
52-week position
24%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+16%
trailing
6-month return
+8%
trailing
YTD return
−5%
this year
Relative strength
+1%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
2 of 161 funds reported for Jun 30 · net +395.9K sh shares · +1 new
Insider flow
Accumulating
Net +$166.9K over 90 days · 0% sells
Short interest
Rising
10.14% of float · ▲ +30.9% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
161 holders — near 3-yr high, broad support
Squeeze score
78
high risk · 0–100
Fundamentals
EPS growth
−57%
Y/Y
Free cash flow
$-113.3M
Balance sheet
$70.9M
net cash
Quant / Vol
risk profile
Volatility
110%
annualized · 1-yr
Max drawdown
−49%
past year
ATR
7.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Up next
Next earnings call
Aug 17, 2026
Est · unconfirmed
· in 6 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed May 14, 2026
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−9%
Bearish
Price vs 50-day avg
−0%
Neutral
RSI (14)
54
Neutral
MACD trend
Positive
Bullish
52-week position
24%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $4 › 200d $4 — 200d above 50d
Institutional flow
Accumulating
2 of 161 funds reported for Jun 30 · net +395.9K sh shares · +1 new
Insider flow
Accumulating
Net +$166.9K over 90 days · 0% sells
Short interest
Rising
10.14% of float · ▲ +30.9% MoM · 5.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
161 holders — near 3-yr high, broad support
Price context
position in its 52-week range
52-wk low $3
Now $4 · 24%
52-wk high $6
vs 200-day avg -9%
vs 50-day avg 0%
Illustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
LRMR
this stock
Larimar Therapeutics, Inc.
|
$375.02M | -5.2% | — | — | 10.1% |
|
ONC
BeOne Medicines Ltd.
|
$446.53B | +1.7% | +22179.2% | 908.7 | 0.1% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$126.50B | +9.9% | +46.2% | 29.6 | 1.8% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$69.50B | -14.0% | +20.8% | 16.2 | 3.2% |
|
ARGX
Argenx SE
|
$57.20B | +8.8% | — | — | 2.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| LRMR | +18.4% | +16.5% | +8.4% | +18.4% | -5.3% |
| SPY | -0.2% | +0.8% | +7.4% | -0.2% | +9.3% |
| vs SPY | +18.5% | +15.6% | +1.0% | +18.5% | -14.6% |